Search Results - "Barbie, David A"

Mechanisms of resistance to immune checkpoint inhibitors by Jenkins, Russell W, Barbie, David A, Flaherty, Keith T

“…Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are…”
Get full text

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade by Aref, Amir R, Campisi, Marco, Ivanova, Elena, Portell, Andrew, Larios, Dalia, Piel, Brandon P, Mathur, Natasha, Zhou, Chensheng, Coakley, Raven Vlahos, Bartels, Alan, Bowden, Michaela, Herbert, Zach, Hill, Sarah, Gilhooley, Sean, Carter, Jacob, Cañadas, Israel, Thai, Tran C, Kitajima, Shunsuke, Chiono, Valeria, Paweletz, Cloud P, Barbie, David A, Kamm, Roger D, Jenkins, Russell W

“…Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for…”
Get more information

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor by Christensen, Camilla L., Kwiatkowski, Nicholas, Abraham, Brian J., Carretero, Julian, Al-Shahrour, Fatima, Zhang, Tinghu, Chipumuro, Edmond, Herter-Sprie, Grit S., Akbay, Esra A., Altabef, Abigail, Zhang, Jianming, Shimamura, Takeshi, Capelletti, Marzia, Reibel, Jakob B., Cavanaugh, Jillian D., Gao, Peng, Liu, Yan, Michaelsen, Signe R., Poulsen, Hans S., Aref, Amir R., Barbie, David A., Bradner, James E., George, Rani E., Gray, Nathanael S., Young, Richard A., Wong, Kwok-Kin

“…Small cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective pharmacological strategies to target SCLC…”
Get full text

Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion by Li, Fengkai, Kitajima, Shunsuke, Kohno, Susumu, Yoshida, Akiyo, Tange, Shoichiro, Sasaki, Soichiro, Okada, Nobuhiro, Nishimoto, Yuuki, Muranaka, Hayato, Nagatani, Naoko, Suzuki, Misa, Masuda, Sayuri, Thai, Tran C, Nishiuchi, Takumi, Tanaka, Tomoaki, Barbie, David A, Mukaida, Naofumi, Takahashi, Chiaki

“…Cancer cell-intrinsic properties caused by oncogenic mutations have been well characterized; however, how specific oncogenes and tumor suppressors impact the…”
Get full text

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer by Jenkins, Russell W, Thummalapalli, Rohit, Carter, Jacob, Cañadas, Israel, Barbie, David A

“…Molecularly targeted therapy and immunotherapy have dramatically changed the landscape of available treatment options for patients with advanced cancer…”
Get full text

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors by Tan, Li, Wang, Jun, Tanizaki, Junko, Huang, Zhifeng, Aref, Amir R, Rusan, Maria, Zhu, Su-Jie, Zhang, Yiyun, Ercan, Dalia, Liao, Rachel G, Capelletti, Marzia, Zhou, Wenjun, Hur, Wooyoung, Kim, NamDoo, Sim, Taebo, Gaudet, Suzanne, Barbie, David A, Yeh, Jing-Ruey Joanna, Yun, Cai-Hong, Hammerman, Peter S, Mohammadi, Moosa, Jänne, Pasi A, Gray, Nathanael S

“…The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation…”
Get full text

ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors by Terai, Hideki, Kitajima, Shunsuke, Potter, Danielle S, Matsui, Yusuke, Quiceno, Laura Gutierrez, Chen, Ting, Kim, Tae-Jung, Rusan, Maria, Thai, Tran C, Piccioni, Federica, Donovan, Katherine A, Kwiatkowski, Nicholas, Hinohara, Kunihiko, Wei, Guo, Gray, Nathanael S, Fischer, Eric S, Wong, Kwok-Kin, Shimamura, Teppei, Letai, Anthony, Hammerman, Peter S, Barbie, David A

“…An increasingly recognized component of resistance to tyrosine kinase inhibitors (TKI) involves persistence of a drug-tolerant subpopulation of cancer cells…”
Get full text

Engineering approaches for studying immune-tumor cell interactions and immunotherapy by Shelton, Sarah E., Nguyen, Huu Tuan, Barbie, David A., Kamm, Roger D.

“…This review describes recent research that has advanced our understanding of the role of immune cells in the tumor microenvironment (TME) using advanced 3D…”
Get full text

Structure and Ubiquitination-Dependent Activation of TANK-Binding Kinase 1 by Tu, Daqi, Zhu, Zehua, Zhou, Alicia Y., Yun, Cai-hong, Lee, Kyung-Eun, Toms, Angela V., Li, Yiqun, Dunn, Gavin P., Chan, Edmond, Thai, Tran, Yang, Shenghong, Ficarro, Scott B., Marto, Jarrod A., Jeon, Hyesung, Hahn, William C., Barbie, David A., Eck, Michael J.

“…Upon stimulation by pathogen-associated inflammatory signals, TANK-binding kinase 1 (TBK1) induces type I interferon expression and modulates nuclear factor κB…”
Get full text

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth by Barbie, Thanh U, Alexe, Gabriela, Aref, Amir R, Li, Shunqiang, Zhu, Zehua, Zhang, Xiuli, Imamura, Yu, Thai, Tran C, Huang, Ying, Bowden, Michaela, Herndon, John, Cohoon, Travis J, Fleming, Timothy, Tamayo, Pablo, Mesirov, Jill P, Ogino, Shuji, Wong, Kwok-Kin, Ellis, Matthew J, Hahn, William C, Barbie, David A, Gillanders, William E

“…Triple-negative breast cancers (TNBCs) are a heterogeneous set of cancers that are defined by the absence of hormone receptor expression and HER2…”
Get full text

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia by Placke, Theresa, Faber, Katrin, Nonami, Atsushi, Putwain, Sarah L., Salih, Helmut R., Heidel, Florian H., Krämer, Alwin, Root, David E., Barbie, David A., Krivtsov, Andrei V., Armstrong, Scott A., Hahn, William C., Huntly, Brian J., Sykes, Stephen M., Milsom, Michael D., Scholl, Claudia, Fröhling, Stefan

“…Chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) trigger aberrant gene expression in hematopoietic progenitors and…”
Get full text

Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade by Gstalder, Cécile, Liu, David, Miao, Diana, Lutterbach, Bart, DeVine, Alexander L, Lin, Chenyu, Shettigar, Megha, Pancholi, Priya, Buchbinder, Elizabeth I, Carter, Scott L, Manos, Michael P, Rojas-Rudilla, Vanesa, Brennick, Ryan, Gjini, Evisa, Chen, Pei-Hsuan, Lako, Ana, Rodig, Scott, Yoon, Charles H, Freeman, Gordon J, Barbie, David A, Hodi, F Stephen, Miles, Wayne, Van Allen, Eliezer M, Haq, Rizwan

“…The molecular mechanisms leading to resistance to PD-1 blockade are largely unknown. Here, we characterize tumor biopsies from a patient with melanoma who…”
Get more information

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer by Nardi, Francesca, Perurena, Naiara, Schade, Amy E, Li, Ze-Hua, Ngo, Kenneth, Ivanova, Elena V, Saldanha, Aisha, Li, Chendi, Gokhale, Prafulla C, Hata, Aaron N, Barbie, David A, Paweletz, Cloud P, Jänne, Pasi A, Cichowski, Karen

“…Despite the success of KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), more effective treatments are needed. One preclinical strategy has been to…”
Get full text

Highly parallel identification of essential genes in cancer cells by Luo, Biao, Cheung, Hiu Wing, Subramanian, Aravind, Sharifnia, Tanaz, Okamoto, Michael, Yang, Xiaoping, Hinkle, Greg, Boehm, Jesse S, Beroukhim, Rameen, Weir, Barbara A, Mermel, Craig, Barbie, David A, Awad, Tarif, Zhou, Xiaochuan, Nguyen, Tuyen, Piqani, Bruno, Li, Cheng, Golub, Todd R, Meyerson, Matthew, Hacohen, Nir, Hahn, William C, Lander, Eric S, Sabatini, David M, Root, David E

“…More complete knowledge of the molecular mechanisms underlying cancer will improve prevention, diagnosis and treatment. Efforts such as The Cancer Genome Atlas…”
Get full text

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer by Yoshida, Ryohei, Saigi, Maria, Tani, Tetsuo, Springer, Benjamin F, Shibata, Hirofumi, Kitajima, Shunsuke, Mahadevan, Navin R, Campisi, Marco, Kim, William, Kobayashi, Yoshihisa, Thai, Tran C, Haratani, Koji, Yamamoto, Yurie, Sundararaman, Shriram K, Knelson, Erik H, Vajdi, Amir, Canadas, Israel, Uppaluri, Ravindra, Paweletz, Cloud P, Miret, Juan J, Lizotte, Patrick H, Gokhale, Prafulla C, Jänne, Pasi A, Barbie, David A

“…Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been…”
Get full text

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer by Ivanova, Elena, Kuraguchi, Mari, Xu, Man, Portell, Andrew J, Taus, Luke, Diala, Irmina, Lalani, Alshad S, Choi, Jihyun, Chambers, Emily S, Li, Shuai, Liu, Shengwu, Chen, Ting, Barbie, Thanh U, Oxnard, Geoffrey R, Haworth, Jacob J, Wong, Kwok-Kin, Dahlberg, Suzanne E, Aref, Amir A, Barbie, David A, Bahcall, Magda, Paweletz, Cloud P, Jänne, Pasi A

“…Evaluating drug responses using primary patient-derived cells represents a potentially rapid and efficient approach to screening for new treatment approaches…”
Get full text

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells by Scholl, Claudia, Fröhling, Stefan, Dunn, Ian F., Schinzel, Anna C., Barbie, David A., Kim, So Young, Silver, Serena J., Tamayo, Pablo, Wadlow, Raymond C., Ramaswamy, Sridhar, Döhner, Konstanze, Bullinger, Lars, Sandy, Peter, Boehm, Jesse S., Root, David E., Jacks, Tyler, Hahn, William C., Gilliland, D. Gary

“…An alternative to therapeutic targeting of oncogenes is to perform “synthetic lethality” screens for genes that are essential only in the context of specific…”
Get full text

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS by Kitajima, Shunsuke, Asahina, Hajime, Chen, Ting, Guo, Sujuan, Quiceno, Laura Gutierrez, Cavanaugh, Jillian D., Merlino, Ashley A., Tange, Shoichiro, Terai, Hideki, Kim, Jong Wook, Wang, Xiaoen, Zhou, Shan, Xu, Man, Wang, Stephen, Zhu, Zehua, Thai, Tran C., Takahashi, Chiaki, Wang, Yujin, Neve, Richard, Stinson, Susanna, Tamayo, Pablo, Watanabe, Hideo, Kirschmeier, Paul T., Wong, Kwok-Kin, Barbie, David A.

“…Despite extensive efforts, oncogenic KRAS remains resistant to targeted therapy. Combined downstream RAL-TBK1 and MEK inhibition induces only transient lung…”
Get full text

Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors by Kim, Dae Joong, Anandh, Swetha, Null, Jamie L., Przanowski, Piotr, Bhatnagar, Sanchita, Kumar, Pankaj, Shelton, Sarah E., Grundy, Erin E., Chiappinelli, Katherine B., Kamm, Roger D., Barbie, David A., Dudley, Andrew C.

“…Targeting DNA methyltransferase 1 (DNMT1) has immunomodulatory and anti-neoplastic activity, especially when paired with cancer immunotherapies. Here we…”
Get full text

Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1 by Chen, Hsiao-Yun, Durmaz, Yavuz T., Li, Yixiang, Sabet, Amin H., Vajdi, Amir, Denize, Thomas, Walton, Emily, Laimon, Yasmin Nabil, Doench, John G., Mahadevan, Navin R., Losman, Julie-Aurore, Barbie, David A., Tolstorukov, Michael Y., Rudin, Charles M., Sen, Triparna, Signoretti, Sabina, Oser, Matthew G.

“…Some small cell lung cancers (SCLCs) are highly sensitive to inhibitors of the histone demethylase LSD1. LSD1 inhibitors are thought to induce their…”
Get full text